Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D2/3 receptor availability in healthy individuals

Molecular Psychiatry(2024)10.1038/s41380-024-02873-2Source: DataRank Database

Genetic risk for treatment resistant schizophrenia and corresponding variation in dopamine synthesis capacity and D2/3 receptor availability in healthy individuals is a research paper published in Molecular Psychiatry (2024). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 0.84)OA: hybridTopics (74)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Rachael K. Blackman,Maria G. Tietcheu,Philip D. Kohn,Jasmin S. Bettina,Bhaskar Kolachana ORCID

Live enrichment

PubMed:39730881 PMC:PMC12092290 OpenAlex:https://openalex.org/W4405844723

U.S. Department of Health & Human Services | NIH | National Institute of Mental Health

Grant: ZIAMH002652

National Institutes of Health

Grant: 1ZIAMH002652-26

Imaging of Neuropsychiatric Disorders with Developmental and Genetic Mechanisms

FWCI

0.84

Citation Percentile

0.8%

Citation Trend

2025

2026

hybridLicense: cc-by

journalhttps://www.nature.com/articles/s41380-024-02873-2.pdf

publisherhttps://www.nature.com/articles/s41380-024-02873-2.pdf

publisherhttps://www.nature.com/articles/s41380-024-02873-2

journalhttps://doi.org/10.1038/s41380-024-02873-2

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39730881

Fields of Study

Schizophrenia research and treatmentFunctional Brain Connectivity StudiesNeurotransmitter Receptor Influence on Behavior0301 basic medicine03 medical and health sciences0302 clinical medicineHumansReceptors, Dopamine D2MaleFemaleReceptors, Dopamine D3AdultDopamineSchizophreniaPositron-Emission TomographyGenetic Predisposition to DiseaseSchizophrenia, Treatment-ResistantCorpus StriatumMiddle AgedDihydroxyphenylalanineCohort StudiesHealthy VolunteersPyrrolidines

MeSH Terms

Schizophrenia, Treatment-ResistantAdultCorpus StriatumDihydroxyphenylalanineDopamineFemaleHumansMaleMiddle AgedPyrrolidinesSchizophreniaCohort StudiesReceptors, Dopamine D2Genetic Predisposition to DiseasePositron-Emission TomographyReceptors, Dopamine D3Healthy Volunteers

Keywords

Dopamine hypothesis of schizophreniaDopamineSchizophrenia (object-oriented programming)Dopamine receptor D2DopaminergicPsychologyPsychosisNeurosciencePutamenNucleus accumbensVentral striatumStriatumDopamine transporterDopamine receptorPsychiatryMedicineInternal medicineMaleAdultPyrrolidinesReceptors, Dopamine D2Receptors, Dopamine D3Middle AgedArticleCorpus StriatumHealthy VolunteersDihydroxyphenylalanineCohort StudiesPositron-Emission TomographySchizophreniaHumansFemaleGenetic Predisposition to DiseaseSchizophrenia, Treatment-Resistant

Sustainable Development Goals

SDG 0: Good health and well-being